Lakefront Biotherapeutics NV: Form 20-F for the period ended Dec 31, 2017
Filed with the SEC on Mar 23, 2018 and accepted by EDGAR at Mar 23, 2018, 16:36 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2017-01-01 to 2017-12-31 | EUR 127.1m | ifrs-full:Revenue |
| Operating income | 12 months2017-01-01 to 2017-12-31 | −EUR 89.8m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2017-01-01 to 2017-12-31 | EUR 198.0k | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2017-01-01 to 2017-12-31 | −EUR 115.7m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | −EUR 2.34 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | −EUR 2.34 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | −EUR 147.0m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | EUR 5.3m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2017-12-31 | $241.3m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2017-12-31 | EUR 1.20bn | ifrs-full:CurrentAssets |
| Total assets | At period end2017-12-31 | EUR 1.29bn | ifrs-full:Assets |
| Current liabilities | At period end2017-12-31 | EUR 171.7m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2017-12-31 | EUR 274.3m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2017-12-31 | EUR 1.01bn | ifrs-full:Equity |
| Shares outstanding | At period end2017-12-31 | 50,936,778 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001558370-18-002364. Last ingested by Listed: Nov 2, 2026, 18:43 ET. Listed shows no prices and gives no investment advice.